MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies Book Value 2011-2026 | BHC
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82 M | 260 M | -34 M | 605 M | 1.14 B | 2.82 B | 5.94 B | 3.26 B | 6.03 B | 5.43 B | 5.23 B | 3.72 B | 4.01 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.03 B | -82 M | 2.95 B |
Quarterly Book Value Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -227 M | -174 M | -82 M | -235 M | 271 M | 145 M | 260 M | 433 M | 253 M | -141 M | -34 M | -135 M | -611 M | -34 M | 605 M | 605 M | 605 M | 605 M | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 2.82 B | 2.82 B | 2.82 B | 2.82 B | 5.94 B | 5.94 B | 5.94 B | 5.94 B | 3.26 B | 3.26 B | 3.26 B | 3.26 B | 6.03 B | 6.03 B | 6.03 B | 6.03 B | 5.4 B | 5.43 B | 5.43 B | 5.43 B | 5.2 B | 5.23 B | 5.23 B | 5.23 B | 3.72 B | 3.72 B | 3.72 B | 3.72 B | 3.93 B | 4.01 B | 4.01 B | 4.01 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.03 B | -611 M | 2.82 B |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
1.71 B | $ 2.71 | 1.12 % | $ 1.4 B |  Canada |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.22 | 4.21 % | $ 45.3 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Harrow Health
HROW
|
52.1 M | $ 41.31 | 1.61 % | $ 1.52 B | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.18 | 2.17 % | $ 127 M | Canada |
 |
Jupiter Wellness
JUPW
|
35 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.5 | -1.64 % | $ 402 M | Canada |
 |
Pacira BioSciences
PCRX
|
778 M | $ 24.76 | 3.77 % | $ 1.15 B | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 4.71 | 3.98 % | $ 304 M | USA |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.52 | 0.33 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.96 | 3.94 % | $ 459 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
Tilray
TLRY
|
3.33 B | $ 6.99 | 2.95 % | $ 4.32 B | Canada |
 |
Veru
VERU
|
32.3 M | $ 2.41 | -2.43 % | $ 325 M | USA |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 2.58 | 0.98 % | $ 340 M | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 0.75 | 0.48 % | $ 3.23 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
94 M | $ 18.02 | - | $ 115 M | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 7.42 | 5.93 % | $ 293 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 1.1 | 4.76 % | $ 54.9 M | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 8.7 | 3.69 % | $ 761 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.32 | 4.98 % | $ 2.88 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 14.57 | 3.96 % | $ 17.5 B | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.71 | 2.77 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
115 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
37 M | $ 0.92 | 0.45 % | $ 33.1 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
22.7 M | $ 0.63 | -5.17 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
26.9 M | $ 2.06 | -0.96 % | $ 23.8 M | USA |